Carisma Therapeutics, Inc.CARMNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank15
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P15
Within normal range
vs 5Y Ago
-6.3x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2024-31.79%
2023214.83%
2022-68.09%
2021477.92%
2020-58.34%
20195.03%
201847.13%
2017-30.92%
201616.10%
201516.28%